Todd M. Morgan

19.8k total citations · 3 hit papers
307 papers, 8.3k citations indexed

About

Todd M. Morgan is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Todd M. Morgan has authored 307 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 203 papers in Pulmonary and Respiratory Medicine, 89 papers in Surgery and 63 papers in Oncology. Recurrent topics in Todd M. Morgan's work include Prostate Cancer Treatment and Research (148 papers), Prostate Cancer Diagnosis and Treatment (131 papers) and Bladder and Urothelial Cancer Treatments (67 papers). Todd M. Morgan is often cited by papers focused on Prostate Cancer Treatment and Research (148 papers), Prostate Cancer Diagnosis and Treatment (131 papers) and Bladder and Urothelial Cancer Treatments (67 papers). Todd M. Morgan collaborates with scholars based in United States, Canada and United Kingdom. Todd M. Morgan's co-authors include Peter E. Clark, Sam S. Chang, Michael S. Cookson, Eva Corey, Daniel A. Barocas, Theodore D. Koreckij, Daniel W. Lin, Daniel E. Spratt, Roger Chou and Ganesh S. Palapattu and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and JAMA.

In The Last Decade

Todd M. Morgan

286 papers receiving 8.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

2017 613 citations Todd M. Morgan et al. profile →
2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review

2023 379 citations Todd M. Morgan et al. European Urology profile →
Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response

2021 199 citations Todd M. Morgan, Ajjai Alva et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Todd M. Morgan United States	46	3.9k	2.5k	2.2k	1.9k	1.4k	307	8.3k
Armen Aprikian Canada	48	4.2k 1.1×	3.0k 1.2×	2.0k 0.9×	2.2k 1.1×	1.4k 0.9×	279	8.7k
Theo M. de Reijke Netherlands	40	3.7k 1.0×	2.6k 1.0×	969 0.4×	1.3k 0.7×	861 0.6×	189	7.5k
Chris H. Bangma Netherlands	56	7.1k 1.8×	2.4k 1.0×	2.1k 0.9×	1.6k 0.9×	978 0.7×	213	9.9k
Jason A. Efstathiou United States	49	5.0k 1.3×	4.9k 2.0×	2.3k 1.0×	1.9k 1.0×	1.1k 0.7×	314	11.4k
James M. McKiernan United States	52	5.1k 1.3×	4.7k 1.9×	2.1k 0.9×	4.3k 2.3×	1.6k 1.1×	340	10.6k
Anil Kapoor Canada	44	5.3k 1.4×	2.1k 0.8×	2.1k 0.9×	4.7k 2.5×	2.3k 1.6×	403	9.9k
Peter Venner Canada	40	4.8k 1.2×	1.8k 0.7×	3.3k 1.5×	1.9k 1.0×	1.5k 1.0×	116	8.4k
Robert C. Flanigan United States	41	5.8k 1.5×	2.1k 0.8×	1.7k 0.8×	3.0k 1.6×	1.7k 1.2×	246	9.0k
Leonard G. Gomella United States	63	6.7k 1.7×	2.6k 1.1×	2.5k 1.1×	3.4k 1.8×	2.5k 1.7×	385	12.7k
Robert K. Nam Canada	44	5.4k 1.4×	1.5k 0.6×	1.5k 0.7×	1.6k 0.9×	1.1k 0.8×	165	8.7k

Countries citing papers authored by Todd M. Morgan

Since Specialization

Citations

This map shows the geographic impact of Todd M. Morgan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Todd M. Morgan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Todd M. Morgan more than expected).

Fields of papers citing papers by Todd M. Morgan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Todd M. Morgan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Todd M. Morgan. The network helps show where Todd M. Morgan may publish in the future.

Co-authorship network of co-authors of Todd M. Morgan

This figure shows the co-authorship network connecting the top 25 collaborators of Todd M. Morgan. A scholar is included among the top collaborators of Todd M. Morgan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Todd M. Morgan. Todd M. Morgan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weiner, Adam B., Andrew J. Armstrong, Alberto Bossi, et al.. (2024). Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review. European Urology. 86(3). 200–210. 13 indexed citations

Tward, Jonathan D., Huei–Chung Huang, Andre Esteva, et al.. (2024). Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital Histopathology. JCO Precision Oncology. 8(8). e2400145–e2400145. 5 indexed citations

Cho, Hyungseok, Seok‐Soo Byun, Nak‐Hoon Son, et al.. (2024). Impact of Circulating Tumor Cell–Expressed Prostate-Specific Membrane Antigen and Prostate-Specific Antigen Transcripts in Different Stages of Prostate Cancer. Clinical Cancer Research. 30(9). 1788–1800. 6 indexed citations

Newcomb, Lisa F., Jeannette M. Schenk, Yingye Zheng, et al.. (2024). Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer. JAMA. 331(24). 2084–2084. 22 indexed citations

Morgan, Todd M., et al.. (2024). Prostate cancer and solid organ transplantation: Patient management and outcomes. European Urology. 85. S341–S341. 1 indexed citations

Vince, Randy, Brittney Cotta, Judith Stangl‐Kremser, et al.. (2023). Analysis of the Tumor Immune Microenvironment (TIME) in Clear Cell Renal Cell Carcinoma (ccRCC) Reveals an M0 Macrophage-Enriched Subtype: An Exploration of Prognostic and Biological Characteristics of This Immune Phenotype. Cancers. 15(23). 5530–5530. 7 indexed citations

Vince, Randy, Merrick Bank, Yilun Sun, et al.. (2023). Evaluation of Social Determinants of Health and Prostate Cancer Outcomes Among Black and White Patients. JAMA Network Open. 6(1). e2250416–e2250416. 46 indexed citations

Tosoian, Jeffrey J., Bruce J. Trock, Ashley E. Ross, et al.. (2022). MyProstateScore in men considering repeat biopsy: validation of a simple testing approach. Prostate Cancer and Prostatic Diseases. 26(3). 563–567. 6 indexed citations

Beckmann, Kerri, Aida Santaolalla, Mikio Sugimoto, et al.. (2022). Risk of progression following a negative biopsy in prostate cancer active surveillance. Prostate Cancer and Prostatic Diseases. 26(2). 403–409. 3 indexed citations

10.

Singhal, Udit, et al.. (2022). Trials in the Key of G: Building Level 1 Evidence on the Real-world Effectiveness of Prostate Biomarkers. European Urology Focus. 8(4). 897–900. 2 indexed citations

11.

Zhu, Kehao, Yingye Zheng, Lisa F. Newcomb, et al.. (2021). Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. Cancer. 128(2). 269–274. 5 indexed citations

12.

Vince, Randy, Ji Qi, Jeffrey J. Tosoian, et al.. (2021). Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative. Prostate Cancer and Prostatic Diseases. 25(4). 677–683. 19 indexed citations

13.

Tosoian, Jeffrey J., Rodney L. Dunn, Yashar S. Niknafs, et al.. (2021). Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study. European Urology Open Science. 29. 30–35. 2 indexed citations

14.

Ginsburg, Kevin, Adam Cole, Michael E. Silverman, et al.. (2019). Should all prostate needle biopsy Gleason score 4 + 4 = 8 prostate cancers be high risk? Implications for shared decision-making and patient counselling. Urologic Oncology Seminars and Original Investigations. 38(3). 78.e1–78.e6. 10 indexed citations

15.

Jung, Younghun, Frank C. Cackowski, Kenji Yumoto, et al.. (2018). CXCL12γ Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes. Cancer Research. 78(8). 2026–2039. 42 indexed citations

16.

Singhal, Udit, Yugang Wang, James Henderson, et al.. (2018). Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Molecular Cancer Research. 16(4). 643–654. 27 indexed citations

17.

Palapattu, Ganesh S., Simpa S. Salami, Andi K. Cani, et al.. (2016). Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer. Clinical Cancer Research. 23(4). 985–991. 17 indexed citations

18.

McDaniel, Andrew S., Daniel H. Hovelson, Andi K. Cani, et al.. (2015). Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy. Cancer Research. 75(24). 5219–5227. 86 indexed citations

19.

Holcomb, Ilona N., Douglas I. Grove, Cynthia Friedman, et al.. (2008). Genomic Alterations Indicate Tumor Origin and Varied Metastatic Potential of Disseminated Cells from Prostate Cancer Patients. Cancer Research. 68(14). 5599–5608. 46 indexed citations

20.

Griffin, Susan, Cynthia A. Lemere, Todd M. Morgan, et al.. (2003). 33rd Annual Meeting of the Society for Neuroscience. 28(12). 799–801. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact